Aditxt (ADTX) to Announce Quarterly Earnings on Wednesday

Posted by George Bondi on Aug 31st, 2026

Aditxt (NASDAQ:ADTX – Get Free Report) is expected to be announcing its results before the market opens on Wednesday, September 2nd. Analysts expect Aditxt to announce earnings of ($224,553,600,000.00) per share and revenue of $1.00 million for the quarter.

Aditxt Price Performance

Aditxt stock opened at $0.01 on Monday. The firm has a market capitalization of $5,548.80, a PE ratio of -0.00 and a beta of 0.95. Aditxt has a one year low of $0.00 and a one year high of $27,092.88.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Weiss Ratings cut Aditxt from a “sell (e+)” rating to a “sell (e)” rating in a report on Wednesday, June 24th. Wall Street Zen raised Aditxt to a “sell” rating in a report on Saturday, May 23rd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

Read Our Latest Report on Aditxt

Insider Buying and Selling

In other Aditxt news, major shareholder Financial Lp Hrt sold 3,132,480 shares of the firm’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $0.01, for a total value of $31,324.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last ninety days, insiders have sold 3,259,267 shares of company stock valued at $32,593. 0.01% of the stock is owned by company insiders.

Aditxt Company Profile

(Get Free Report)

Aditxt, Inc is a clinical-stage biotechnology company focused on the development and commercialization of natural antimicrobial peptides and microbiome-based detection technologies. Leveraging proprietary peptide libraries, the company aims to provide novel solutions for infection prevention and control across healthcare, food safety, animal health and agricultural markets. Aditxt’s approach centers on harnessing peptides that can disrupt microbial cell membranes without promoting resistance, addressing a growing need for alternatives to traditional antibiotics and chemical disinfectants.

The company’s product offerings include contract-based microbial detection and identification services, designed to help hospitals, food processors and other regulated industries monitor contamination levels and validate hygiene protocols.